Back Hepatitis C

Hepatitis C

INHSU 2015 Highlights Hepatitis C Prevention and Treatment for People Who Inject Drugs

An international group of researchers, healthcare providers, advocates, people who use drugs, and people living with hepatitis C are gathering this week in Sydney for the 4th International Symposium on Health Care in Substance Users, focusing on hepatitis C prevention, care, and treatment for injection drug users. The full program, with links to many of the presentations, is available online. Follow conference news on Twitter #INHSU2015.


People Who Inject Drugs Should Have Access to Hepatitis C Treatment, Expert Panel Recommends

New recommendations on hepatitis C treatment and care encourage physicians to offer treatment to all people who inject drugs who are diagnosed with HCV infection, and to offer a comprehensive package of social support and harm reduction to enable people to adhere to treatment. The recommendations are published this month in the International Journal of Drug Policy, coinciding with the 4th International Symposium on Hepatitis Care in Substance Users taking place this week Sydney, which focuses on the management of hepatitis among drug users.


Achillion's Odalasvir with Sofosbuvir Cured Hepatitis C in 6-8 Weeks in Phase 2 Study

Achillion Pharmaceuticals' experimental NS5A inhibitor odalasvir (ACH-3102) plus Gilead Science's sofosbuvir (Sovaldi), taken without ribavirin, produced sustained virological response at 12 weeks post-treatment in all previously untreated genotype 1 hepatitis C patients treated for 6 or 8 weeks in a small Phase 2 study, according to a recent company announcement. Treatment was safe and well-tolerated.


Coverage of 2015 Interscience Conference on Antimicrobial Agents and Chemotherapy coverage of the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, September 17-21, 2015.

Highlights of this year's conference include experimental antiretroviral drugs and treatment strategies, HIV prevention, and comorbidities among people with HIV and HIV/HCV coinfection.

Full listing by topic

ICAAC website



Gilead's Sofosbuvir + Velpatasvir Combo Shows Good Results in Phase 3 Trials

A dual combination of Gilead Sciences' sofosbuvir (Sovaldi) and new pangenotypic HCV NS5A inhibitor velpatasvir (GS-5816) taken for 12 weeks produced cure rates of 95% to 100% for people with hepatitis C genotypes 1 through 6, including patients with compensated liver cirrhosis, in the ASTRAL trials, the company announced this week. People with decompensated cirrhosis, however, did better when they added ribavirin.


Hepatitis C Cure Associated with Improvement in Liver Fibrosis in People with HIV/HCV Coinfection

A successful response to hepatitis C virus (HCV) therapy is associated with a significant improvement in liver stiffness among people with HIV and HCV coinfection, French investigators report in the September 10 online edition of AIDS.


ICAAC 2015: New Hepatitis C NS5A Inhibitor Looks Promising in Early Studies

A new hepatitis C virus (HCV) NS5A inhibitor being developed by Enanta -- EDP-239 -- was well-tolerated and demonstrated promising antiviral activity against genotype 1 HCV in a single-dose monotherapy study presented at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) last week in San Diego.


Cost of Comprehensive Global Hepatitis Prevention and Treatment Might Peak at $11 Billion in 2025

Reaching the World Health Organization’s (WHO) proposed targets for viral hepatitis control by 2030 could require global funding of US$11 billion per year by 2025, Stefan Wiktor of the WHO Hepatitis Program told the World Hepatitis Summit in Glasgow earlier this month.


Sexual Transmission of HCV Is Increasing Among Gay and Bi Men with HIV

Sexual transmission of hepatitis C virus (HCV) is occurring among HIV-positive men who have sex with men, associated with receptive anal sex and non-injection drug use, and a small subset of men may be prone to recurrent infection after being cured of hepatitis C, according to a meta-analysis reported in the August 7 online edition of AIDS.